CLEAR GUIDANCE ON PRACTICAL CONSIDERATIONS WITH LIXIANA®

Practical guidance for managing patients prescribed LIXIANA® including management of bleeding complications and specific warnings and precautions.1

Increasing renal function in NVAF
A trend towards decreasing efficacy with increasing creatinine clearance was observed for LIXIANA® compared to well-managed warfarin. Therefore, LIXIANA® should only be used in patients with NVAF and high creatinine clearance after a careful evaluation of the individual thromboembolic and bleeding risk.

Assessment of renal function:
CrCl should be monitored at the beginning of the treatment in all patients and afterwards when clinically indicated.

  •  *

    Reporting rates are based on the female population in clinical trials. Vaginal bleeds were reported commonly in women under the age of 50 years, while it was uncommon in women over the age of 50 years.

Reference (click to access full publication)